BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270226
DTSTAMP:20261028T115729Z
CREATED:20261028T115729Z
LAST-MODIFIED:20261028T115729Z
UID:44627-1803340800-1803599999@www.pharmajournalist.com
SUMMARY:3rd Annual TRP Target Selection & Drug Design Summit
DESCRIPTION:The 3rd Annual TRP Target Selection & Drug Design Summit is the industry-dedicated discovery and preclinical forum for advancing the next generation of targeted radiopharmaceutical therapies. Taking place in Boston from February 23-25\, 2027\, the summit will unite more than 100 experts from across discovery\, biology\, medicinal chemistry\, radiochemistry\, ADME/DMPK\, toxicology\, radiobiology\, dosimetry\, preclinical development\, translational science\, and business development. \nAs established targets such as PSMA become increasingly crowded\, the meeting will help radiopharmaceutical developers identify novel targets\, explore new disease settings\, and create differentiated candidates with stronger clinical potential. Attendees will examine how clinically validated targets from ADCs\, RDCs\, immuno-oncology\, and other targeted modalities can be assessed and translated into radioligand therapy programs. \nThe agenda will explore emerging targets across CAIX\, MSLN\, the brain\, extracellular matrix\, and leukocytes\, alongside the biological factors that determine suitability for radiopharmaceutical development. Discussions will also cover targeting moieties\, linkers\, chelators\, radionuclide selection\, biodistribution\, kinetic imaging\, total-body PET\, digital SPECT\, computational biology\, dosimetry\, organ-specific toxicity\, and preclinical safety strategy. \nTwo interactive pre-conference workshops will provide focused learning on using advanced imaging and computational biology to identify high-potential targets\, as well as mining clinical validation from other therapeutic modalities to accelerate target selection. Across the main conference\, presentations\, roundtables\, case studies\, and networking sessions will help attendees benchmark candidate design and determine the evidence required to advance programs confidently toward the clinic. \nWith contributions from experts representing Bayer\, AstraZeneca\, Molecular Partners\, Mariana Oncology\, Harvard Medical School\, United Theranostics\, Ratio Therapeutics\, Affibody\, and other leading organizations\, the summit offers a focused opportunity to improve target selection\, strengthen drug design\, and build safer\, more differentiated radiopharmaceutical pipelines. \nTo know more visit: https://ter.li/ugtcnsbo
URL:https://www.pharmajournalist.com/event/3rd-annual-trp-target-selection-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270224
DTEND;VALUE=DATE:20270226
DTSTAMP:20261110T132343Z
CREATED:20261110T132343Z
LAST-MODIFIED:20261110T132343Z
UID:44746-1803427200-1803599999@www.pharmajournalist.com
SUMMARY:5th Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:The 5th Annual Viral Vector Process Development & Manufacturing Summit brings together leaders across CMC\, process development\, manufacturing\, MSAT\, operations\, and regulatory affairs to advance robust\, reliable\, and reproducible viral vector manufacturing platforms. As the industry shifts towards optimizing proven AAV and LVV platforms\, the summit focuses on overcoming the challenges of scalable manufacturing\, process consistency\, regulatory readiness\, and commercial success. \nThrough real-world case studies\, scientific presentations\, panel discussions\, and networking opportunities\, attendees will explore strategies to improve vector yield\, enhance empty/full capsid separation\, optimize transfection and purification processes\, reduce cost of goods\, and accelerate development timelines through platform-based manufacturing approaches. \nThe summit will showcase practical insights from leading biopharma and biotech organizations including Regeneron\, Sanofi\, Ultragenyx\, Legend Biotech\, Cabaletta Bio\, and Apertura Gene Therapy\, providing attendees with actionable strategies to strengthen manufacturing performance\, improve product quality\, and support successful clinical and commercial outcomes. \nJoin a community of viral vector experts dedicated to increasing productivity\, reducing manufacturing and CMC burden\, and building the scalable processes needed to deliver the next generation of cell and gene therapies. \nFind out more today and secure your complimentary ticket: https://ter.li/2pthcqqz
URL:https://www.pharmajournalist.com/event/5th-viral-vector-process-development-manufacturing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR